{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T09:29:19Z","timestamp":1786958959681,"version":"build-2736575974"},"reference-count":30,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T00:00:00Z","timestamp":1786752000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Oral antiviral agents nirmatrelvir\/ritonavir (NMV\/r) and molnupiravir are recommended for the early treatment of non-hospitalized adults with COVID-19 who are at increased risk of disease progression. Real-world comparative data on these two agents remain limited. The aim of this study was to evaluate the efficacy and safety of NMV\/r and molnupiravir in non-hospitalized patients with COVID-19. Materials and Methods: We conducted a retrospective, single-center study with a sample size of 122 initially non-hospitalized adults with confirmed SARS-CoV-2 infection treated at the Clinic for Infectious Diseases, University Clinical Center of Vojvodina (UCCV), Novi Sad, Serbia, during 2022. Patients were treated within the first five days of symptom onset with either NMV\/r (n = 48) or molnupiravir (n = 74) for five days. Demographic characteristics, clinical presentation, comorbidities, vaccination status, laboratory parameters at baseline and on day 3, chest radiography findings, hospitalization, and mortality were analyzed. Statistical analysis was performed using the Statistical Package for the Social Sciences (SPSS), version 21 (IBM Corp., Armonk, NY, USA). Results: The groups did not differ significantly in age, sex, vaccination status, or vaccine type. Between baseline and day 3, the increase in lymphocyte count (p &lt; 0.001) was significantly greater in the molnupiravir group. Chest radiography showed no significant between-group differences. Overall, 6 patients (4.9%) were hospitalized, with no significant difference between antiviral agents (p = 1.000), and no deaths occurred. Among patient-reported symptoms effects, the incidence of dysgeusia was significantly higher in patients treated with NMV\/r (p = 0.001). Conclusions: Both antivirals showed similarly low progression, hospitalization, and mortality rates.<\/jats:p>","DOI":"10.3390\/medicina62081566","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T08:05:41Z","timestamp":1786953941000},"page":"1566","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Safety of Nirmatrelvir\/Ritonavir and Molnupiravir in Non-Hospitalized Patients with COVID-19: A Single-Center Retrospective Study"],"prefix":"10.3390","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1772-5564","authenticated-orcid":false,"given":"Maria","family":"Pete","sequence":"first","affiliation":[{"name":"Faculty of Medicine, University of Novi Sad, 21000 Novi Sad, Serbia"},{"name":"Clinic for Infectious Diseases, University Clinical Center of Vojvodina, 21000 Novi Sad, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4323-1776","authenticated-orcid":false,"given":"Dajana","family":"Lendak","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Novi Sad, 21000 Novi Sad, Serbia"},{"name":"Clinic for Infectious Diseases, University Clinical Center of Vojvodina, 21000 Novi Sad, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8886-3542","authenticated-orcid":false,"given":"Nadica","family":"Kova\u010devi\u0107","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Novi Sad, 21000 Novi Sad, Serbia"},{"name":"Clinic for Infectious Diseases, University Clinical Center of Vojvodina, 21000 Novi Sad, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Pastorna\u010dki","sequence":"additional","affiliation":[{"name":"Clinic for Infectious Diseases, University Clinical Center of Vojvodina, 21000 Novi Sad, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6013-4649","authenticated-orcid":false,"given":"Milica","family":"Milovac","sequence":"additional","affiliation":[{"name":"Clinic for Anesthesia, Intensive Care and Pain Therapy, University Clinical Center of Vojvodina, 21000 Novi Sad, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4283-0363","authenticated-orcid":false,"given":"Vedrana","family":"Petri\u0107","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Novi Sad, 21000 Novi Sad, Serbia"},{"name":"Clinic for Infectious Diseases, University Clinical Center of Vojvodina, 21000 Novi Sad, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Bodea, R., Void\u0103zan, T.S., Ferencz, L.I., and \u00c1br\u00e1m, Z. (2025). Comorbidities and severe COVID-19 outcomes: A retrospective analysis of hospitalized patients in three counties in Romania. Microorganisms, 13.","DOI":"10.3390\/microorganisms13040787"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"102674","DOI":"10.5501\/wjv.v14.i2.102674","article-title":"COVID-19 management in patients with comorbid conditions","volume":"14","author":"Sanyaolu","year":"2025","journal-title":"World J. Virol."},{"key":"ref_3","unstructured":"Centers for Disease Control and Prevention (2025, June 15). People with Certain Medical Conditions and COVID-19 Risk Factors, Available online: https:\/\/www.cdc.gov\/covid\/risk-factors\/index.html."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s10238-022-00821-4","article-title":"Comorbidities and clinical complications associated with SARS-CoV-2 infection: An overview","volume":"23","author":"Gupta","year":"2023","journal-title":"Clin. Exp. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e03647-20","DOI":"10.1128\/mBio.03647-20","article-title":"Comorbidities in SARS-CoV-2 patients: A systematic review and meta-analysis","volume":"12","author":"Ng","year":"2021","journal-title":"mBio"},{"key":"ref_6","first-page":"E329","article-title":"Age-related risk factors and severity of SARS-CoV-2 infection: A systematic review and meta-analysis","volume":"62","author":"Rahman","year":"2021","journal-title":"J. Prev. Med. Hyg."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.1007\/s12325-025-03218-3","article-title":"Therapeutic approaches for COVID-19: A review of antiviral treatments, immunotherapies, and emerging interventions","volume":"42","author":"Alves","year":"2025","journal-title":"Adv. Ther."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3201\/eid3001.230414","article-title":"Effectiveness of vaccines and antiviral drugs in preventing severe and fatal COVID-19, Hong Kong","volume":"30","author":"Cheung","year":"2024","journal-title":"Emerg. Infect. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Flisiak, R., Jaroszewicz, J., Kozielewicz, D., Kuchar, E., Parczewski, M., Paw\u0142owska, M., Piekarska, A., Rzymski, P., Simon, K., and Tomasiewicz, K. (2025). Management of SARS-CoV-2 infection-Clinical practice guidelines of the Polish Association of Epidemiologists and Infectiologists, for 2025. J. Clin. Med., 14.","DOI":"10.3390\/jcm14072305"},{"key":"ref_10","first-page":"CD015381","article-title":"Molnupiravir for treating COVID-19","volume":"10","author":"Tatz","year":"2025","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.cmi.2024.10.026","article-title":"Real-world effectiveness of nirmatrelvir-ritonavir and molnupiravir in non-hospitalized adults with COVID-19: A population-based, retrospective cohort study","volume":"31","author":"Jorda","year":"2025","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.jmii.2025.03.015","article-title":"Effectiveness of molnupiravir as early treatment for COVID-19 to prevent mortality and hospitalisation in high-risk adults: A systematic review and meta-analysis of randomised trials and real-world studies involving 1,612,082 patients","volume":"58","author":"Lin","year":"2025","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"102329","DOI":"10.1016\/j.dsx.2021.102329","article-title":"Molnupiravir in COVID-19: A systematic review of literature","volume":"15","author":"Singh","year":"2021","journal-title":"Diabetes Metab. Syndr."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"ofaf449","DOI":"10.1093\/ofid\/ofaf449","article-title":"Patient-reported outcomes of nirmatrelvir treatment for high-risk, nonhospitalized adults with symptomatic COVID-19","volume":"12","author":"Ansari","year":"2025","journal-title":"Open Forum Infect. Dis."},{"key":"ref_15","unstructured":"European Medicines Agency (2026, June 30). COVID-19 Guidance: Research and Development. Available online: https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/public-health-threats\/coronavirus-disease-covid-19\/covid-19-public-health-emergency-international-concern-2020-23\/guidance-medicine-developers-and-other-stakeholders-covid-19\/covid-19-guidance-research-development."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Gentile, I., Scotto, R., Schiano Moriello, N., Pinchera, B., Villari, R., Trucillo, E., Ametrano, L., Fusco, L., Castaldo, G., and Buonomo, A.R. (2022). Nirmatrelvir\/ritonavir and molnupiravir in the treatment of mild\/moderate COVID-19: Results of a Real-life study. Vaccines, 10.","DOI":"10.1101\/2022.08.23.22278585"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3967","DOI":"10.2147\/IDR.S477083","article-title":"A real-world retrospective study on the efficacy and safety of four antiviral drugs for hospitalized covid-19 patients: Nirmatrelvir\/ritonavir, simnotrelvir\/ritonavir, molnupiravir and azvudine","volume":"17","author":"Yu","year":"2024","journal-title":"Infect. Drug Resist."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"102620","DOI":"10.1016\/j.eclinm.2024.102620","article-title":"Comparison of safety and efficacy between nirmatrelvir-ritonavir and molnupiravir in the treatment of COVID-19 infection in patients with advanced kidney disease: A retrospective observational study","volume":"72","author":"Chu","year":"2024","journal-title":"EClinicalMedicine"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"6049","DOI":"10.18632\/aging.103000","article-title":"Does comorbidity increase the risk of patients with COVID-19: Evidence from meta-analysis","volume":"12","author":"Wang","year":"2020","journal-title":"Aging"},{"key":"ref_20","unstructured":"Aleem, A., Olarewaju, O., and Pozun, A. (2025, June 15). Evaluating and Referring Patients for Outpatient Monoclonal Antibody Therapy for Coronavirus in The Emergency Department (Archived). 25 January 2023, StatPearls, Available online: https:\/\/pubmed.ncbi.nlm.nih.gov\/34662075\/."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.15420\/ecr.2024.04","article-title":"Cardiovascular drug interactions with nirmatrelvir\/ritonavir for COVID-19: Considerations for daily practice","volume":"19","author":"Ferri","year":"2024","journal-title":"Eur. Cardiol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Mazzitelli, M., Mengato, D., Sasset, L., Ferrari, A., Gardin, S., Scaglione, V., Bonadiman, N., Calandrino, L., Cavinato, S., and Trivellato, S. (2023). Molnupiravir and nirmatrelvir\/ritonavir: Tolerability, safety, and adherence in a retrospective cohort study. Viruses, 15.","DOI":"10.3390\/v15020384"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Sun, J., Deng, X., Huang, J., He, G., and Huang, S. (2024). Data mining of adverse drug event signals with nirmatrelvir\/ritonavir from FAERS. PLoS ONE, 19.","DOI":"10.1371\/journal.pone.0316573"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e70043","DOI":"10.1002\/pds.70043","article-title":"Investigating the safety profile of fast-track COVID-19 drugs using the FDA Adverse Event Reporting System database: A comparative observational study","volume":"33","author":"Kim","year":"2024","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e347","DOI":"10.3346\/jkms.2023.38.e347","article-title":"Effectiveness and adverse events of nirmatrelvir\/ritonavir versus molnupiravir for COVID-19 in outpatient setting: Multicenter prospective observational study","volume":"38","author":"Park","year":"2023","journal-title":"J. Korean Med. Sci."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.4103\/jfmpc.jfmpc_1699_23","article-title":"Lymphocyte as a predictor of prognosis of COVID-19 patients: A hospital-based study","volume":"13","author":"Biakhlupuii","year":"2024","journal-title":"J. Fam. Med. Prim. Care"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Daenen, K., van Hooijdonk, S., Tong-Minh, K., Dik, W.A., van Hagen, P.M., Huijben, J.A., Gommers, D., van Gorp, E.C.M., Endeman, H., and Dalm, V.A.S.H. (2024). Exploring lymphocyte subsets in COVID-19 patients: Insights from a tertiary academic medical center with a high proportion of patients on immunosuppression. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1436637"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Wen, X.S., Jiang, D., Gao, L., Zhou, J.Z., Xiao, J., Cheng, X.C., He, B., Chen, Y., Lei, P., and Tan, X.W. (2021). Clinical characteristics and predictive value of lower CD4+T cell level in patients with moderate and severe COVID-19: A multicenter retrospective study. BMC Infect. Dis., 21.","DOI":"10.1186\/s12879-020-05741-w"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e2335077","DOI":"10.1001\/jamanetworkopen.2023.35077","article-title":"Nirmatrelvir or molnupiravir use and severe outcomes from omicron infections","volume":"6","author":"Lin","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Zhao, H., Meng, W., Lv, X., Si, S., Wu, S., Li, J., Cai, Z., Jin, R., Yang, L., and Li, C. (2026). Nirmatrelvir\/ritonavir reduced mortality in severe or critical COVID-19 patients: A multicenter retrospective cohort study. Front. Med., 13.","DOI":"10.3389\/fmed.2026.1747565"}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/8\/1566\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T09:13:15Z","timestamp":1786957995000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/8\/1566"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,15]]},"references-count":30,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["medicina62081566"],"URL":"https:\/\/doi.org\/10.3390\/medicina62081566","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,15]]}}}